Tag: $Novavax

Novavax beat Wall Street expectations for second-quarter revenue on Wednesday, helped by a $175 million milestone payment related to U.S. approval of its COVID-19 vaccine in May.

Novavax stock is rising after the vaccine maker posted quarterly results above analysts expectations early Thursday.

Novavax cut its annual revenue forecast on Tuesday, citing lower-than-expected sales of its COVID-19 vaccine, ahead of handing over the rights to sell the shot to French drugmaker Sanofi.

 Novavax on Thursday cut its revenue forecast for 2024 as it anticipated lower sales of its COVID-19 vaccine, including the company’s updated shot for the fall season targeting the JN.1 variant.

Novavax on Friday said it has signed a multibillion-dollar deal with French drugmaker Sanofi to co-commercialize the company’s Covid vaccine starting next year and develop combination shots targeting the coronavirus and the flu, among other efforts. 

Vaccine maker Novavax on Wednesday reported fourth-quarter revenue and earnings that missed Wall Street’s estimates and reiterated plans to cut costs as it fights to stay afloat. 

Novavax Inc said on Tuesday its updated protein-based COVID-19 vaccine generated an immune response against the “Eris” subvariant in preclinical studies.

Novavax on Tuesday posted an unexpected second-quarter profit on earlier-than-expected revenue from its COVID-19 vaccine, but still trimmed its full-year forecast for sales of the shot.

Shares of Covid-19 manufacturer Novavax were surging after the company said it will receive $350 million from Canada to settle forfeited vaccine doses that were supposed to be delivered.

Novavax said Tuesday that it would cut around a quarter of its workforce as it reported a steeper fall in revenue than expected for the first quarter of the year. Shares surged as investors bet the move could save enough money to to allow the Covid-19 vaccine manufacturer to bring new shots to the market.